Streetbeat News

Earnings

GSK

GSK reaffirms its 2024 financial outlook, expecting turnover growth of 7%-9%, core operating profit growth of 11%-13%, and core EPS growth of 10%-12%. The company revises expectations for its segments, with vaccines expected to decrease slightly, specialty medicines to increase significantly, and general medicines to grow moderately.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:39 am

GSK

GSK reported Q3 2024 earnings per share of $1.29, surpassing the analyst estimate of $1.23, but sales of $10.418 billion fell short of the $10.781 billion estimate. Both earnings and sales showed slight year-over-year growth.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:35 am

ENZ

Enzo Biochem reported a Q4 loss of $(0.01) per share with sales of $7.53 million and cash reserves of $52.4 million.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 8:19 am

META

SNAP

Snap Inc. reported strong growth in daily active users and promising results from new ad formats and the 'Simple Snapchat' layout during its Q3 earnings call. The company surpassed revenue and earnings expectations, despite a 45% stock decline this year.

Portfolio Pulse from Ananya Gairola

October 30, 2024 | 7:27 am

SKFRY

SKF anticipates a mid-single-digit organic sales decline year-over-year for both Q4 and fiscal year 2024. The company also expects a negative currency impact on operating profit and plans significant capital expenditures.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:36 am

SKFRY

SKF reported Q3 adjusted EPS of $0.39, beating the $0.35 estimate, but sales of $2.27B missed the $2.44B estimate. EPS decreased by 7.14% from last year, and sales decreased by 4.61%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:28 am

UBS

UBS anticipates a mid-single-digit decline in Q4 net interest income for Global Wealth Management and a low single-digit drop in Personal & Corporate Banking. The macroeconomic outlook remains uncertain due to geopolitical conflicts and upcoming US elections. Integration-related expenses are expected to be around USD 1.2bn.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:19 am

UBS

UBS Group reported Q3 2024 earnings of $0.43 per share, significantly beating the analyst estimate of $0.22. Sales also surpassed expectations, reaching $12.334 billion against the $11.132 billion estimate.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:12 am

CAT

MCD

META

MSFT

PFE

SBUX

The Nasdaq Composite reached a record high ahead of major tech earnings, while the CNN Money Fear and Greed index remained in the 'Greed' zone. Pfizer and McDonald's reported better-than-expected Q3 earnings. Investors are anticipating earnings from Meta, Microsoft, Caterpillar, and Starbucks.

Portfolio Pulse from Avi Kapoor

October 30, 2024 | 6:11 am

SDZNY

Sandoz has raised its 2024 net sales growth guidance to high-single digits in constant currency, driven by strong biosimilars and generics demand. The company maintains its core EBITDA margin guidance at approximately 20%.

Portfolio Pulse from Benzinga Newsdesk

October 30, 2024 | 6:07 am